Nuvectis Pharma (NVCT) Equity Average (2021 - 2026)

Nuvectis Pharma has disclosed Equity Average across 6 years of filings, most recently posting $16.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $16.3 million, up 6.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.3 million (up 6.41% YoY), and the FY2025 annual result was $14.1 million, up 28.35% from the prior year.
• Equity Average came in at $16.3 million for Q1 2026 at Nuvectis Pharma, down from $21.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $21.2 million in Q4 2025 to a low of $1.8 million in Q1 2022.
• The 5-year median for Equity Average is $15.3 million (2025), against an average of $14.8 million.
• Across the five-year window, Equity Average surged 687.84% in 2022 and tumbled 36.47% in 2024, its largest moves.
• Nuvectis Pharma's Equity Average stood at $17.3 million in 2022, then declined by 16.49% to $14.4 million in 2023, then declined by 28.33% to $10.4 million in 2024, then surged by 104.9% to $21.2 million in 2025, then declined by 23.08% to $16.3 million in 2026.
• The last three Equity Average figures came in at $16.3 million (Q1 2026), $21.2 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.